Fmr LLC Cor Medix Inc. Transaction History

Fmr LLC

$1.68 Trillion
Q2 2025

A detailed history of Fmr LLC transactions in Cor Medix Inc. stock. As of the latest transaction made, Fmr LLC holds 7,776 shares of CRMD stock, worth $78,848. This represents 0.0% of its overall portfolio holdings.

Number of Shares

7,776

Previous 6,818 14.05%

Holding current value

$78,848

Previous $41,000 131.71%

% of portfolio

0.0%

Previous 0.0%

13 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2025 Aug 14, 2025	BUY	$5.86 - $16.56 $5,613 - $15,864	958 Added 14.05%	7,776 $95,000
Q1 2025 May 12, 2025	SELL	$6.16 - $12.57 $93,231 - $190,246	-15,135 Reduced 68.94%	6,818 $41,000
Q4 2024 Feb 13, 2025	BUY	$8.1 - $13.59 $140,413 - $235,582	17,335 Added 375.38%	21,953 $177,000
Q3 2024 Nov 13, 2024	BUY	$3.64 - $8.23 $5,915 - $13,373	1,625 Added 54.29%	4,618 $37,000
Q2 2024 Aug 13, 2024	BUY	$4.08 - $6.39 $1,562 - $2,447	383 Added 14.67%	2,993 $12,000
Q1 2024 May 13, 2024	SELL	$2.94 - $4.24 $1,658 - $2,391	-564 Reduced 17.77%	2,610 $11,000
Q4 2023 Feb 13, 2024	BUY	$3.0 - $4.01 $7,989 - $10,678	2,663 Added 521.14%	3,174 $11,000
Q3 2023 Nov 13, 2023	BUY	$3.6 - $4.46 $1,540 - $1,908	428 Added 515.66%	511 $1,000
Q2 2023 Aug 11, 2023	BUY	$3.94 - $5.8 $291 - $429	74 Added 822.22%	83 $0
Q4 2022 Feb 13, 2023	SELL	$2.81 - $4.45 $514 - $814	-183 Reduced 95.31%	9 $0
Q3 2022 Nov 10, 2022	SELL	$2.82 - $7.52 $31 - $82	-11 Reduced 5.42%	192 $1,000
Q2 2022 Aug 12, 2022	SELL	$2.73 - $5.61 $4,818 - $9,901	-1,765 Reduced 89.68%	203 $1,000
Q1 2022 May 13, 2022	BUY	$3.83 - $6.24 $7,537 - $12,280	1,968 New	1,968 $11,000

Others Institutions Holding CRMD

# of Institutions

182

Shares Held

32.7M

Call Options Held

867K

Put Options Held

561K

View Full List

About CorMedix Inc.

Ticker CRMD
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 41,208,200
Market Cap $418M
Description
CorMedix Inc., a biopharmaceutical company, focuses on developing and commercializing therapeutic products for the prevention and treatment of infectious and inflammatory diseases in the United States and internationally. Its lead product candidate is DefenCath/Neutrolin, a novel anti-infective solution for the reduction and prevention of cathet...

More about CRMD

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Fmr LLC, based on Form 13F filings with the SEC.

News

Stay updated on Fmr LLC with notifications on news.

Account